|
| LLO mutants | Effects of mutations on cell death | Effects of mutations on proinflammatory activity | Effects of mutations on LLO Immunogenicity | Reference |
|
Single amino acids substitutions | LLO C484A | A decrease of 28% in the hemolytic activity | ND | ND | [58] |
LLO C484S | A decrease of 85% in the hemolytic activity | ND | NA | [20, 58] |
LLO W491A | A decrease of 95% in the hemolytic activity and abolished capacity to induce apoptosis | ND | ND | [20, 58, 59] |
LLO 415 (domains 1–3, no nomain 4) | Loss of cytolytic and lethal activities | ND | ND | [59] |
LLO W492A | A decrease of 99% in the hemolytic activity | ND | Retains the ability to be efficiently presented by APC’s | [18, 58, 59] |
LLO W491-492A | A decrease of 99.5% in the hemolytic activity | ND | Retains the ability to be efficiently presented by APC’s | [18] |
LLO W489A | Cytolytic activity diminished | ND | ND | [59] |
dtLLO (3 punctual mutations: C484A, W491A, and W492A. | No hemolytic activity | Retain the proinflammatory activity | ND | [29] |
LLOA40W, LLOS44D, LLOS44E, LLO D394W | Increased the hemolytic activity | ND | ND | [2] |
LLOK175E, LLOE262K, LLOS176W, LLOD4 (domain 4) | No hemolytic activity | ND | ND | [2] |
LLOE262W | No effect on cytolytic activity | ND | ND | [2] |
LLON230W | A decrease of 50% in the hemolytic activity | ND | ND | [2] |
|
LLO truncated forms | Deletion of PPII region: LLODPPII. | Increased the hemolytic activity | ND | ND | [2] |
rLLO493, rLLO482, rLLO415; (Forms deficient of C-terminal region) | No hemolytic activity | Retain the proinflammatory activity | ND | [12] |
rLLO416–529 (domain 4 alone) | No hemolytic activity | No influence on proinflammatory activity | ND | [12] |
rLLO59–415 include the sequence 59–415aa of LLO) | No hemolytic activity | Retain the proinflammatory activity | ND | [12] |
|